| Автор | Pool, James, L. |
| Дата выпуска | 1990 |
| dc.description | Numerous clinical and laboratory studies have shown that selective α1-adrenergic receptor blocking agents lower blood pressure by reducing increased total peripheral vascular resistance. Terazosin, a new, long-acting selective α1-adrenergic antagonist, has been shown to be effective in the treatment of mild to moderate essential hypertension. Its pharmacokinetic and pharmacodynamic characteristics are similar to those of prazosin, except that terazosin has a longer plasma elimination half-life, which allows once-daily administration. Both terazosin monotherapy and terazosin in combination with other antihypertensive agents have been shown to produce sustained mean systolic and diastolic blood pressure reductions in supine and standing positions. Terazosin was generally well tolerated during short-term and long-term clinical trials. There were no clinically significant laboratory abnormalities with long-term oral administration of the drug. Moreover, terazosin did not produce significant changes in supine or standing heart rates, and syncope was very uncommon with terazosin monotherapy. The α1-adrenoreceptor antagonists tend to reduce total and low-density lipoprotein (LDL) cholesterol levels, lower triglyceride levels, and increase high-density lipoprotein (HDL) cholesterol levels. Since elevated levels of total cholesterol, LDL cholesterol, and triglyceride increase a patientʼs risk of coronary heart disease, α1-adrenoreceptor antagonists should be considered as first-line therapy for hypertensive patients with abnormal, elevated baseline lipid values. |
| Издатель | SAGE Publications |
| Тема | Terazosin |
| Тема | α1-adrenoreceptors |
| Тема | lipoproteins |
| Тема | hypertension |
| Тема | quinazolines |
| Тема | coronary artery disease |
| Название | Implications of Selective α1-Adrenoreceptor Blockade in the Management of Hypertension: Appropriate Candidates for Trial |
| Тип | Journal Article |
| DOI | 10.1177/104252689000200508 |
| Print ISSN | 1042-5268 |
| Журнал | Journal of Vascular Medicine and Biology |
| Том | 2 |
| Первая страница | 268 |
| Последняя страница | 274 |
| Выпуск | 5 |
| Библиографическая ссылка | Langer SZ, Hicks PE.Alpha-adrenoreceptor subtypes in blood vessels: physiology and pharmacology.J Cardiovasc Pharmacol1984;6(Suppl 4):S547–58. |
| Библиографическая ссылка | Insel PA.Adrenergic receptors: evolving concepts on structure and function.Am J Hypertens1989; 2:112S–118S. |
| Библиографическая ссылка | Lefkowitz RJ, Caron MG.Adrenergic receptors: models for the study of receptors coupled to guanine nucleotide regulatory proteins.J Biol Chem1988;263:4993–96 |
| Библиографическая ссылка | McGrath J, Wilson V.α-Adrenoceptor subclassification by classical and response-related methods: same question, different answers.Trends Pharmacol Sci1988;9:162–65 |
| Библиографическая ссылка | Exton JH.Mechanisms involved in α-adrenergic phenomena.Am J Physiol1985;248:E633–47. |
| Библиографическая ссылка | Colucci WS.New developments in alpha-adrenergic receptor pharmacology: implications for the initial treatment of hypertension.Am J Cardiol1983;51(Suppl):639–43. |
| Библиографическая ссылка | Pool JL, Lenz ML, Taylor AA.α1-Adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.J Human Hypertens1990; in press. |
| Библиографическая ссылка | Winn M, Kyncl J, Dunnigan DA, et al. U.S. Patent 4,026, 894, 1977. |
| Библиографическая ссылка | Kyncl JJ, Hollinger RE, Oheim KW, Winn M.(Abbott-45975), 2-[4-((tetrahydro-2-furanyl)carbonyl)-l-piperazinyl]-6,7-dimethoxy-4-quinazolinamine HCl, a new antihypertensive agent of the quinazoline type (abstr).Pharmacologist1980,22:272. |
| Библиографическая ссылка | Kyncl JJ, Bush EN, Buckher SA.Terazosin, a new quinazoline antihypertensive agent. II. Alpha-adrenergic blocker properties. In: Rosenthal J, ed. Focus on alpha blockade and terazosin.Munich: Zuckschwerdt Berlat, 1986. |
| Библиографическая ссылка | Moser M, ed. Advances in the management of hypertension: focus on terazosin, a new α1-adrenergic antagonist.Am J Med1986;80(Suppl 5B):1–105. |
| Библиографическая ссылка | Reid JL, Vincent J.Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.Cardiology1986;73:164–74 |
| Библиографическая ссылка | Titmarsh S, Monk JP.Terazosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.Drugs1987;33:461–77 |
| Библиографическая ссылка | Luther RR.New perspectives on selective α1 blockade.Am J Hypertens1989;2:729–35 |
| Библиографическая ссылка | Pool JL, Nelson EB, Taylor AA, Mitchell JR.Terazosin (Hytrin): cumulative experience of clinical trials in the USA for the treatment of mild to moderate essential hypertension.Br J Clin Pract1987;41(Suppl 54):9–14. |
| Библиографическая ссылка | Dauer AD.Terazosin: an effective once-daily monotherapy for the treatment of hypertension.Am J Med1986;80(Suppl 5B):29–34. |
| Библиографическая ссылка | Drayer JIM, Weber MA, DeYoung JL, Brewer DD.Long-term BP monitoring in the evaluation of antihypertensive therapy.Arch Intern Med1983;143:898–901 |
| Библиографическая ссылка | Deger G.Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension.Am J Med1986;80(Suppl 5B):62–67. |
| Библиографическая ссылка | Chrysant SG.Experience with terazosin administered in combination with other antihypertensive agents.Am J Med1986;80(Suppl 5B):55–61. |
| Библиографическая ссылка | Holtzman JL, Kaihlanen PM, Rider JA, Lewin AJ, Spindler JS, Oberlin JA.Concomitant administration of terazosin and atenolol for the treatment of essential hypertension.Arch Intern Med1988,148:539–43 |
| Библиографическая ссылка | Mersey JH.Long-term experience with terazosin for treatment of mild to moderate hypertension.Am J Med1986;80(Suppl 5B):68–72. |
| Библиографическая ссылка | Sperzel WD, Glassman HN, Jordan DC, Luther RR.Overall safety of terazosin as an antihypertensive agent.Am J Med1986;80(Suppl 5B):77–81. |
| Библиографическая ссылка | Pool JL, Nelson EB, Taylor AA, Mitchell JR.Alpha-1 adrenergic blockade changes plasma lipids in man.Clin Res1982;30:213A. |
